Skyrizi continues to outperform as AbbVie looks to fill Humira gap

Despite the effects of the COVID-19 outbreak, AbbVie now expects 2020 sales of psoriasis drug Skyrizi to reach about $1.4 billion as the therapy again exceeded expectations in the year’s first quarter, suggesting the company will likely have a blockbuster drug to help offset future generic competition for its top seller Humira.

In its earnings report Friday, AbbVie Inc. (NYSE:ABBV) said sales of Skyrizi risankizumab-rzaa were $300 million in 1Q20, up 39% sequentially from $216 million in 4Q19 and beating analysts’ consensus of $276.6 million. The new full-year estimate exceeds AbbVie’s guidance in February of $1.2 billion for the year...